Xeris Biopharma Holdings, Inc. (XERS) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Xeris Biopharma is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its primary commercial products are Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company is also advancing XP-8121, a once-weekly subcutaneous levothyroxine candidate.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $83,127 | $60,119 |
| Net Income (Loss) | $2,234 | $(9,220) |
| Operating Income (Loss) | $7,916 | $(3,090) |
| Net Cash from Operating Activities | $9,870 | $(10,031) |
| Cash and Cash Equivalents | $111,750 | $58,440 |
| Long-term Debt (Net) | $221,224 | $220,335 |
| Accumulated Deficit | $(669,073) | $(681,081) |
Margins: Gross margin (excluding amortization) improved to approximately 87.2% in Q1 2026 compared to 84.9% in Q1 2025. Operating margin turned positive at 9.5%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38.3% year-over-year, driven primarily by a 94.9% surge in Recorlev net revenue ($49.8M vs. $25.5M). This growth was attributed to higher patient volume and favorable net pricing.
- Profitability: The company reported a net income of $2.2 million, a significant turnaround from a net loss of $9.2 million in the prior year. Operating income improved by $11.0 million.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 20.7% to $53.1 million, largely due to increased personnel costs to support commercial expansion. R&D expenses increased 13.3% to $8.8 million.
- Cash Flow: Operating cash flow swung from a $10.0 million outflow in Q1 2025 to a $9.9 million inflow in Q1 2026, driven by higher product sales.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash resources ($111.8M) are sufficient to sustain operations for at least the next twelve months. However, the company maintains an accumulated deficit of $669.1 million and may require additional financing in the future.
- Debt Obligations: The company holds $33.6 million in 2028 Convertible Notes and approximately $189.5 million in term loans (2029 Loans). The 2029 Loans carry a floating interest rate with an effective rate of approximately 11.4%.
- Legal Proceedings: Xeris filed patent infringement lawsuits in February and March 2026 against Torrent, Somerset, Sandoz, and Zydus regarding generic versions of Recorlev. These filings triggered automatic 30-month stays on FDA approval for the generic applications.
- Outlook: The company expects to continue incurring net losses in the near term due to commercialization costs, R&D activities, and high interest rates, despite current profitability.
Investor Verification Checklist
- Recorlev Sustainability: Verify if the 95% revenue growth in Recorlev is sustainable or driven by temporary pricing/volume spikes.
- Debt Maturity Profile: Review the terms of the 2029 Loans, specifically the potential acceleration clause if 2028 Convertible Notes are not redeemed by January 2028.
- Patent Litigation: Monitor the status of the Hatch-Waxman lawsuits filed against generic filers for Recorlev.
- Inventory Valuation: Note the $9.1 million inventory reserve and the $1.4 million write-down of expired/excess inventory included in COGS.
- Customer Concentration: Confirm that the top four customers continue to represent approximately 98% of gross product revenue.